

Curriculum vitae

Ilaria Grassi

Address: -

Email: -

PERSONAL STATEMENT

Nuclear medicine physician with expertise in scintigraphy, PET/CT, both with routine tracers and with new ones, radionuclide therapy with somatostatin analogues labelled with ^{90}Y e ^{177}Lu , with ^{131}I for thyroid benign and malignant neoplasms and radioimmunotherapy for lymphomas.

Interested in scientific divulgation, as attested by the numerous publications published as first and second author. Reviewer for: Cancer, Current oncology, Diagnostics, Journal of Clinical Medicine and Nutrients.

Quality Management System referent for Nuclear Medicine Therapy Unit, Romagna Institute for the Study of Tumors "Dino Amadori" - IRST S.r.l., Meldola, FC, Italy

Expert physician in PNEI (PSICONEUROENDOCRINOIMMUNOLOGY) and PNEISystem[®]

EMPLOYMENT HISTORY

02/01/2019-today Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST Institution of hospitalization and scientific care (IRCCS) S.r.l, via P. Maroncelli 40, Meldola (FC) ITALY Nuclear Medicine Unit: Nuclear medicine physician full-time staff

- Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors through somatostatin analogues radiolabeled with ^{177}Lu
- Radioligand therapy (RLT) for advanced prostatic tumors through ^{177}Lu PSMA
- Radionuclide therapy with alpha emitters (^{223}Ra) for bone metastasis in prostate cancer
- collaboration in research activities, through the collection, insertion and processing of data of experimental treatment protocols, and collaboration in writing scientific papers.

15/12/2016- 01/01/2019 Local Health Authority (LHA) of Romagna, Viale Stradone 9, Faenza Faenza (RA), ITALY Nuclear Medicine Unit, Nuclear medicine physician.

- Scintigraphic imaging (brain, bone, cardiac, renal, surrenal, thyroid, sentinel node and radioguided occult lesions localization and radiolabeled leucocytes)
- Being thyroid lesions therapy with ^{131}I
- Thyroid ultrasonography

11/04/2016-13/12/2016 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"- IRST S.r.l IRCCS, Meldola (FC) Nuclear Medicine Unit: Nuclear medicine physician

- Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors through somatostatin analogues radiolabeled with ^{177}Lu and ^{90}Y
- Radionuclide therapy with alpha emitters (^{223}Ra) for bone metastasis in prostate cancer

21/09/2015-31/03/2016 Santa Maria Nuova Hospital, IRCCS, via Amendola 2, Reggio Emilia ITALY Nuclear Medicine Unit recognised as “Center of Excellence for “PET applications in Radiation Oncology”, Nuclear medicine physician

- Scintigraphic imaging (brain, bone, cardiac, renal, surrenal, thyroid, sentinel node and radioguided occult lesions localization and radiolabeled leucocytes)
- Benign thyroid lesions therapy with 131 I
- PET/CT imaging with different radiopharmaceutical: 18F-Fluorodesossiglucose (18F-FDG) , 18F-choline e con 68Ga- DotaTOC)
- Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors through somatostatin analogues radiolabeled with 177Lu and 90Y

16/03/2015- 19/05/2015 Bologna University Hospital, via Albertoni 2, Bologna ITALY, Nuclear Medicine Unit. Collaboration assignment for the project “Role of 18F-FLT in patients with suspect lymphoma relapse”

30/06/2009- 10/12/2014 Bologna University Via Zamboni, 33 Bologna/ Bologna University Hospital , nuclear medicine resident

- Scintigraphic imaging (brain, bone, cardiac, renal, surrenal, thyroid, sentinel node and radioguided occult lesions localization)
- PET/CT imaging with 18 F-FDG, 11C-choline, 11C-metionine, 68 Gallio-dotaNOC, 18f -anti 1-amino-3-fluorine 18-fluorocyclobutane- 1-carboxylic acid (FACBC), 18f - flurotimidina (FLT), 64 cu Copper(II)-diacetyl- bis(N4-methylthiosemicarbazone, ATSM), 18f -diidrossifenilanina (F-DOPA),
- Therapy with 90Y- microsphere .

17/12/2007- 16/9/2008 Bologna University, Department of Internal Medicine and Gastroenterology, Endocrinology unit, bursary for the reseacrh project “ Hyperandrogenic states in adolescence and young age”

EDUCATION

- MASTER

28/01/2022 First level master in PNEI (PSICONEUROENDOCRINOIMMUNOLOGY) and PNEISystem[®] obtained at the Pneisystem Academy[®], Rome, Title of Pneisystem Expert[®]

- SPECIALIZATION

11/12/2014 Bologna University Nuclear medicine specialization (110/110 cum laude). Dissertation title: "The role of PET/CT with 18F-FDG in the incidental detection of intestinal lesions: correspondence between abnormal tracer accumulation and histopathological data", supervisor prof S. Fanti

- DEGREE

13/11/2006 Medicine and Surgery degree, (110/110), Dissertation title: “Prevalence and characterization of hyperandrogenisms in a donor population", supervisor prof. Renato Pasquali)

- HIGH SCHOOL DIPLOMA

14/07/2000 Secondary-school diploma at Liceo Scientifico Statale ISS Ferdinando F.Muscogiuri (100/100)

- EDUCATION COURSES

- Academic year 2011/2012 English language course at University Language Center Bologna University

-2010-2011 English language course at cultural circle “ Il chiostro” Bologna

2-CV dr. Ilaria Grassi

- 1/4/2007 - 30/6/2007: traineeship qualifying for the medical profession at Sant'Orsola Malpighi University Hospital

13-15 settembre 1999: summer school at "Scuola superiore di studi universitari e di perfezionamento S. Anna di Pisa", Volterra (PI)

- **TRAINING COURSES**

1) Nutrition, lifestyle and nitric oxide donors : synergy of intent with the objective of "prevention", Rimini, April 12 2008

2) Patient care path with type 2 diabetes mellitus and metabolic syndrome: health, scientific and management aspects, Bentivoglio (BO), 10/11/2007

3) Update on radiation protection, Bologna 27/11/2008

4) 2 Italian congress resident in nuclear medicine, Bologna 27 June 2009

5) New trend in molecular imaging and nuclear medicine, Bologna, 14 September 2009

6) First Medical Nuclear Days in Romagna, Bertinoro 12 2 13 November 2009

7) Osteomyelitis and prosthetic infections, Ferrara, 4 December 2009

8) Recent advances in molecular imaging and therapy, Bolzano, 07/05/2010

9) pet to the future , Bologna 19 July 2013

10) VI meeting pet metabolic imaging for a modern radiotherapy, Arcispedale Santa Maria Nuova-IRCCS Reggio Emilia 11 April 2014

11) 23rd annual congress of EANM Vienna, 9 October-13 October 2010.

12) Second Medical Nuclear Days in Romagna, Bertinoro 28 and 29 April 2011

13) Third Romagna Nuclear Medical Days, Bertinoro 26 and 27 April 2012

14) 26th annual congress of eanm , lyon, france 19-23 October 2013,

15) and new imaging in cancer patients, Brindisi, 9 and 10 November 2012

16) XI AIMN National Congress , Turin, 1-4 March 2013

17) Fourth medical nuclear days in Romagna, Bertinoro 16 and 17 September 2013

18) Multidisciplinary management on the subject of target therapy in breast cancer, 5th edition, Bologna, 13 and 14 December 2012

19) Radiometabolic therapy: in which direction? Ferrara, 19 September 2014

20) Quinte giornate medico nucleari romagnole (Bertinoro, 25 and 26 September 2014)

21) Radiotherapy and hyperbaric medicine: radiosensitivity and toxicity management, Ferrara, 5 December 2014.

22) XII National Congress aimn 2015, 17 and 18 April 2015, Rimini

3-CV dr. Ilaria Grassi

- 23) Gran rounds in nuclear medicine , Ferrara, 15 May 2015
- 24)XXV EUROPEAN CONGRESS OF NUCLEAR MEDICINE, MILAN, 27-31 October 2012
- 25) Meeting between nuclear physicians, endocrinologists and oncologists related to the radiometabolic therapy center, Arcispedale Santa Maria Nuova-IRCCS Reggio Emilia 12 February 2015
- 26) Young investigator meeting of the European Association of nuclear medicine 2015, Vienna, 16 and 17 July 2015
- 27) Corso fad della AIMN " PET/MRI a new era in multimodality molecular imaging ", 12/10/2015, 7 credits ECM
- 28) Meet the professor, Rita de Santis: "avidinox base cancer therapies: turning old drugs into new killers", IRST IRCCS Meldola, 19/05/2016.
- 29) Prostate cancer unit: opportunity in romagna- 1 year later, IRST IRCCS Meldola, 25/05/2016
- 30) Pain therapy in oncology: interactions and compatibility between drugs, meldola, 7 June 2016
- 31) Lights & shadows of prostate cancer imaging, Bologna, 23-24 June 2016
- 32) XIII AIMN National Congress, Rimini, 2-4 March 2017
- 33) Seven medical-nuclear days in Romagna , Bertinoro, 20 and 21 April 2017
- 34) EANM congress 2017, vienna, 21-25 October 2017
- 35) Eighth medical nuclear days in Romagna, Bertinoro, 17 and 18 May 2018
- 36) Discussion of complex or didactic clinical cases traditional nuclear medicine and metabolic radio therapy, 31 January 2015- 31 December 2015, Arcispedale Santa Maria Nuova-IRCCS Reggio Emilia, 10 credits ECM
- 37) Progress of Nuclear Medicine in Oncology: Importance of Target, Modena 10/11/2017, 5 credits ecm
- 38) Clinical cases in pediatric nephrology, Faenza, 15/12/2017 (internal course USL Romagna)
- 39) General training of workers, e-learning course, certificate issued by Azienda USL Reggio Emilia, 12/01/2015
- 40) Safety and Health for health workers (ex art.37 del D.Lgs 81/2008) and principles on infectious risk management , MOD A+MOD B, Ravenna, 9/11/2017 e 13/11/2017, total 14 credits ecm, (internal course company USL Romagna)
- 41) Reasoned reading of Law n.219 of 22 December 2017 "Rules on informed consent and early treatment provisions", Academy of Palliative Medicine, Campus Bentivoglio Bologna, 29/05/2018
- 42) Professional liability and insurance implications in the light of L.24/2017, Cesena 30/05/2018 (internal company course USL Romagna)
- 43) Residential training course "GCP and quality aspects in the conduct of clinical trials", 26 November 2015 Reggio Emilia, Scientific Director of the event dr Massimo Costantini, scientific director IRCCS, 7 ECM credits.
- 44) distance education course "Vaccines 2.0: The White Paper", 25/05/2021, 50 ECM credits
- 45) distance education course "Our body: a container of nutrients and toxic", 13/05/2021, 50 ECM credits
- 46) distance education course "COVID AND NUCLEAR MEDICINE", 13/04/2021, 3 credits ECM

- 47) MEETINGS WITH THE D.LGS. N 101 OF 31/07/2020, 18/11/2020, 6 credits ecm
- 48) distance education course :Violence on Health Care Workers, 10.4 ecm credits
- 49) New coronavirus distance education course: all the necessary information, 7.8 ecm credits, 0403/2020
- 50) distance education: Health Opportunities course: strategies, skills and tools
- 51) distance education :Therapy course in Nuclear Medicine: liver tumors and neuroendocrine tumors, 5/10/18, 8 credits ecm
- 52) distance education - EU Regulation 2016/679 on the protection of personal data V. 01 4 10-12-2018-31-12-2019 3 credits ecm I Definitive Provider Azienda USL della Romagna
- 53)Irst field training Clinical discussion meeting, indication to therapy, activities to be administered and follow up 1 07/01/2019-20/12/2019 50 credits ecm I Definitive Provider Azienda USL della Romagna
- 54) distance education: Prevention of transmission of infectious agents in health organizations Ver.02 1 16/01/2019-31/12/19 18 ECM CREDITS I Provider definitive Company USL of Romagna
- 55) distance education: - Medical device monitoring system Ver.02 1 21/01/2019-31/12/2019 6 ECM CREDITS
- 56) [IRST] The Infectious Risk 12/02/2019 2 CREDITS ECM I Provider definitive Company USL of Romagna
- 57) [IRST] Let's talk about Clear: principles and practices for the promotion of Health Literacy in the paths of diagnosis and oncological care 1 14/10/2019-21/10/2019 7.8 ECM CREDITS I Provider definitive Company USL of Romagna
- 58) distance education - Good Clinical Practice Principles Base 2019 1 25/10/2019-31/12/2019 405 ECM I Definitive Provider Azienda USL della Romagna
- 59) distance education : Training Course Clinical Record Oncology 3 26/11/2019 2 CREDITS ECM I Provider definitive Company USL of Romagna
- 60) distance education: The Quality Management System in 'pills' 1 02/01/2020-31/12/2020 2 ECM CREDITS I Final Provider Azienda USL della Romagna
- 61) Field Training [IRST] Clinical discussion meeting, indication to therapy, activities to be administered and follow up 1 9/01/2020-02/12/2020 50 ECM I Final Provider Azienda USL della Romagna
- 62) distance education :PNEI: pathophysiology, integrated diagnosis and systemic therapies focused on epigenetics 01/03/2022 50 CREDITS ECM
- 63) "Good clinical practice, from theory to practice", 15/06/2023 IRST Meldola

SCIENTIFIC INTERESTS

Research protocols

- At IRST/IRCCS study IRST100.19, IRST 100.11, IRST100.26 , IRST 100.06, IRST185.03
- At Arcispedale Santa Maria Nuova Reggio Emilia DOTA2013/DOTATER .
- At Bologna University Hospital , Predictive role of hypoxia marker PET/CT imaging (64Cu-ATSM) in patients with NSCLC and candidates for chemo and/or radiotherapy, Role of PET/CT with 64cu-ATSM in the detection of hypoxic areas in head neck neoplasms, Innovation of imaging techniques in

clinical practice: role of magnetic resonance imaging (MRI) with diffusion study (DWI) and double tracer PET (FDG and 11C-Choline) in the management of patients with primary liver cancer"/"Improvement of the clinical practice: innovative imaging technique, "Role of 18F-FLT in patients with suspect lymphoma relapse".

Oral presentations

-"Target volume delineation in patients with head and neck (h&n) cancer: impact of 64cu-ATSM vs FDG PET/CT", XI italian nuclear medicine congress, Torino 1-4 marzo 2013,

-"68Ga-labeled PSMA (vs 18F-Chol) in recurrent and advanced prostate cancer: a prospective study", Young Investigator Meeting 2015, Vienna, 16 and 17 July 2015

List of printed publications

1) **Grassi I**, Castellucci P, Nanni C, Ghedini P, Ambrosini V, Allegri V, Montini GC, Guidalotti PL, Fanti S. Incidentally detected increased fdg uptake in bowel and its correlation with hystopathological data: our experience in a case series study. *curr radiopharm*. 2014 ; 7(2):107-114

2) **I.Grassi**, C.Nanni, G.Cicoria, C.Biasi, Feisal Bunkheila, E.Lopci. P. M. Colletti, D.Rubello and S.Fanti. Usefulness of 64Cu-ATSM in Head and Neck Cancer . A preliminary prospective study. *Clin Nucl Med* 2014; 39: e59-e63.

3) **I. Grassi**, JJ Morigi, C. Nanni and Stefano Fanti "FDG and other Radiopharmaceutical in the evaluation of liver lesions", *Clinical and translational imaging* (2014), DOI 10.1007/s40336-014-0059-x

4) **Grassi I**, Nanni C, Allegri V, Morigi JJ, Montini GC, Castellucci P, Fanti S. THE clinical use of PET with (11)C-acetate .*Am J Nucl Med Mol Imaging*. 2012;2(1):33-47. Epub 2011 Dec 15.2012;2(1):33-47.

5) **Grassi I**, Nanni C, Vicennati V, Castellucci P, Allegri V, Montini GC, Pagotto U, di Dalmazi G, Pasquali R, Fanti S.I-123 MIBG scintigraphy and 68Ga-DOTANOC PET/CT negative but F-18 DOPA PET/CT positive pheochromocytoma: a case report.*Clin Nucl Med*. 2011 Feb;36(2):124-6. doi: 10.1097/RLU.0b013e318203bc4f.

6) Severi S, **Grassi I**, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. *Onco Targets Ther*. 2017 Jan 27;10:551-557. doi: 10.2147/OTT.S97584. Review. PubMed PMID: 28203088; PubMed Central PMCID: PMC5293504.

7) S. Fanti, **I. Grassi**, P. Caroli: La medicina nucleare: attualità e prospettive, *giornale Associazione Nazionale Medici Direzioni Ospedaliere*, n.3/2011.

8) Lopci E, **Grassi I**, Rubello D, Colletti PM, Cambioli S, Gamboni A, Salvi F, Cicoria G, Lodi F, Dazzi C, Mattioli S, Fanti S. Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT. *Clin Nucl Med*. 2016 Feb;41(2):e87-92. doi: 10.1097/RLU.0000000000001017.

9) Lopci e, **Grassi i**, Chiti a, nanni c , Cicoria g, Toschi I, Fonti c, Lodi f, Mattioli s, Fanti s. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. *Am J Nucl Med Mol Imaging* 2014;4(4):365-384 www.ajnmml.us/ISSN:2160-8407/ajnmml0000557

10) Meignan M, Cottreau AS, Versari A, Chartier L, Dupuis J, Boussetta S, **Grassi I**, Casasnovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. *J Clin Oncol*. 2016 Aug 22. pii: JCO669440. [Epub ahead of print] PubMed PMID: 27551111.

- 11) Meignan M, Cottureau AS, Versari A, Chartier L, Dupuis J, Boussetta S, **Grassi I**, Casanovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J. Reply to H.J.A. Adams et al and E. Laffon et al. *J Clin Oncol*. 2017 Mar 10;35(8):920-923. doi: 10.1200/JCO.2016.71.0459. PubMed PMID: 28029310.
- 12) Lopci E, Grizzi F, Russo C, Toschi L, **Grassi I**, Cicoria G, Lodi F, Mattioli S, Fanti S. Early and delayed evaluation of solid tumours with ⁶⁴Cu-ATSM PET/CT: a pilot study on semiquantitative and computer-aided fractal geometry analysis. *Nucl Med Commun*. 2017 Apr;38(4):340-346. doi: 10.1097/MNM.0000000000000656.
- 13) Gambineri A, Repaci A, Patton L, **Grassi I**, Pocognoli P, Cognigni GE, Pasqui F, Pagotto U, Pasquali R. Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. *Nutr Metab Cardiovasc Dis*. 2009 Dec;19(11):797-804. doi: 10.1016/j.numecd.2009.01.007. Epub 2009 pr 9.
- 14) Gambineri A, Semple RK, Forlani G, Genghini S, **Grassi I**, Hyden CS, Pagotto U, O'Rahilly S, Pasquali R. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. *Eur J Endocrinol*. 2008 Sep;159(3):347-53. doi: 10.1530/EJE-08-0272
- 15) Belli ML, Mezzenga E, Di Iorio V, Celli M, Caroli P, Canali E, Matteucci F, Tardelli E, **Grassi I**, Sansovini M, Nicolini S, Severi S, Cremonesi M, Ferrari M, Paganelli G, Sarnelli A. A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods *J Vis Exp*. 2020 Apr 24;(158). doi: 10.3791/60477. (ORIGINAL ARTICLE)
- 16) Paganelli G, Sansovini M, Nicolini S, **Grassi I**, Ibrahim T, Amadori E, Di Iorio V, Monti M, Scarpi E, Bongiovanni A, Altini M, Urso L, Cittanti C, Matteucci F, Severi S. 177 Lu-PRRT in Advanced Gastrointestinal Neuroendocrine Tumors: 10-year Follow-Up of the IRST Phase II Prospective Study *Eur J Nucl Med Mol Imaging* 2020 May 29. doi: 10.1007/s00259-020-04873-0. Online ahead of print. (ORIGINAL ARTICLE)
- 17) Martine Bocchini , Fabio Nicolini , Stefano Severi , Alberto Bongiovanni, Toni Ibrahim , Giorgia Simonetti , **Ilaria Grassi** , Massimiliano Mazza Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. *Front Oncol* . 2020 May 27;10:831. doi: 10.3389/fonc.2020.00831. eCollection 2020.
- 18) Bongiovanni A, Maiorano BA, Azzali I, Liverani C, Bocchini M, Fausti V, Di Menna G, **Grassi I**, Sansovini M, Riva N, Ibrahim T. Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. *Pharmaceuticals (Basel)*. 2021 May 17;14(5):476. doi: 10.3390/ph14050476. PMID: 34067837; PMCID: PMC8155858.
- 19) Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, Monti M, Caroli P, Sarnelli A, Diano D, Di Iorio V, Grana CM, Cittanti C, Pieri F, Severi S, Paganelli G. Combined use of ¹⁷⁷Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. *Eur J Nucl Med Mol Imaging*. 2021 Feb 18. doi: 10.1007/s00259-021-05236-z. Epub ahead of print. PMID: 33604690.
- 20) Marini I, Sansovini M, Bongiovanni A, Nicolini S, **Grassi I**, Ranallo N, Monti M, Di Iorio V, Germanó L, Caroli P, Sarnelli A, Paganelli G, Severi S. Theragnostic in neuroendocrine tumors. *Q J Nucl Med Mol Imaging*. 2021 Dec 9. doi: 10.23736/S1824-4785.21.03426-9. Epub ahead of print. PMID: 34881852.
- 21) Lechner M et al. (**Grassi I**) Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma, *European Journal of Cancer*, <https://doi.org/10.1016/j.ejca.2021.09.046> Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

22) Bocchini M, Tazzari M, Ravaioli S, Piccinini F, Foca F, Tebaldi M, Nicolini F, Grassi I, Severi S, Calogero RA, Arigoni M, Schrader J, Mazza M, Paganelli G. Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors. *Front Oncol.* 2023 May 23;13:1136331. doi: 10.3389/fonc.2023.1136331. PMID: 37287922; PMCID: PMC10242108.

Abstracts or posters presented at courses, congresses and conferences

- 1) **I.Grassi**, C.Nanni , S.Nicolini, G. Cicoria , F. Bunkheila, C. Blasi, R. Mazzarotto, S. Fanti. Target volume delineation in patients with Head and Neck (H&N) cancer: impact of 64Cu-ATSM vs FDG PET/CT. Clinical and translational imaging (2013) 1 (suppl1): S1-S38
- 2) **I. GRASSI**, P. GHEDINI, P. CASTELLUCCI, C. NANNI, V. AMBROSINI, V. ALLEGRI , G.C. MONTINI, P.L. GUIDALOTTI and S. FANTI . Abnormal and increased FDG uptake in bowel and its correlation with bioptical results: our experience, *Eur J Nucl Med* (2014) 41 (Suppl 2): S151-S705.
- 3) **Grassi I**, Fonti C, Gianstefani A, Pecorelli A, Ghedini P, Castellucci P, Bolondi L, Golfieri R, Fanti S. the role of double tracer PET/CT in comparison with ci in evaluating patients with hcc: preliminary results, *Clin Transl Imaging* (2015) 3 (Suppl 1):S1–S144
- 4) **I. Grassi**, C. Nanni, S. Matteo, S. Nicolini, A. Paccapelo, V. Ambrosini, S. Fanti. The impact of 11C-Methionine PET/CT in comparison with Conventional Imaging (CI) in patients (pts) with glioblastoma: preliminary results. *Eur J Nucl Med*, volume 2, suppl. 2, October 2011.
- 5) C. NANNI, **I. GRASSI**, G. CICORIA, V. AMBROSINI, A. CECCONI, P. CASTELLUCCI, G. MONTINI, V. ALLEGRI, C. PETTINATO, E. BARBIERI, S. FANTI. 64Cu-at-sm pet/ct and 18f-fdg pet/ct in patients with h&n cancer candidate to radiotherapy: preliminary results. *Eur J Nucl Med Mol Imaging* (2010) 37 (suppl2): S333-S481.
- 6) Ghedini P., **Grassi I.** , Diodato S., Tabacchi E., Castellucci P., Fanti S., The role of 18f-fdg pet/ct for detection of suspect recurrence of schwannoma after treatment. , *Eur J Nucl Med* (2014) 41 (suppl 2): s151-s705
- 7) Lopci e, **Grassi I**; Cambioli S; Gamboni A; Salvi F; Cicoria G; Lodi F; Dazzi C; Mattioli S; Fanti s. 64cu-at-sm pet/ct in solid tumours: a prognostic evaluation for disease outcome *ejnmmi* (2015)vol 42 suppl1, s131
- 8) E. Lopci, A. Cistaro, L. Guerra, A. Piccardo, C. Nanni, R. Burnelli, P. Castellucci, P. Zucchetta, E. Derenzini, A. M. Maffione, P. Caroli, **I. Grassi**, S. Fanti. Predictive factors in paediatric HD: the role of 18F-FDG PET. *Eur J Nucl Med Mol Imaging* (2010) 37 (suppl2): S198-S311
- 9) A. Cecconi, C. Nanni, F. Bunkheila, **I.Grassi**, A.Guido, S. Fanti, E.Barbieri. 64Cu-at-sm PET/CT and 18F-FDG-PET/CT in the staging and target volume delineation for Head and Neck cancer (H&N); 811 poster Radiotherapy and Oncology - RADIOOTHER ONCOL. 01/2011; 99.
- 10) Fuccio C, Castellucci P., Santi I, Caroli P, **Grassi I**, Lopci E, Celli M, Nicolini S, Fantini L and Fanti S Role of 11C-Choline PET/CT in the restaging of prostate cancer patients with biochemical relapse and negative results at conventional imaging methods. *JNM* 2010; 51(supplement 2):1271.
- 11) Fuccio C, Castellucci P, Celli M, Zukerman Z, Zanoni L, nicolini S, **Grassi I**, De Vivo S, boschi S, Fanti S. PET/CT with ¹¹C Choline : potential application in patients with very early relapse and PSA lower than 1 ng/ml . The quarterly Journal of nuclear medicine and molecular imaging , vol 55 – suppl1, n 2, april 2011.LU.0b013e318203bc4f.

12) L. Zanoni, E. Lopci, M.Celli, S. De Vivo, P.Caroli, L. Fantini, S. Nicolini, **I.Grassi**, V. Ambrosini, I. Santi, C. Fuccio, C.Fonti, S.Fanti,. End-treatment PET evaluation in follicular lymphoma patient. *Eur J Nucl Med Mol Imaging* (2011) 38 (Suppl 2): S93-S228.

13)J.J. Morigi; V. Ambrosini; P. Caroli; M. Zompatori; C. Nanni; S. Salvelli; **I. Grassi**; F. Ceci; L. Zanoni; S. Fanti. ¹⁸F-FDG PET/CT Role in Fever of Unknown Origin. *Clinical and translational imaging*, (2013) 1 (suppl1): S39-S140.

14) Lopci E, Grizzi F; **Grassi I**; Russo C; Cicoria G; Cambioli S;Lodi F; Chiti a ;Mattioli S; Fanti S Early and late evaluation of solid tumours with 64cu-atm pet/ct: a computer-aided fractal analysis.

ejnm vol 42 suppl1, s222-223

15)Ghedini P, Nanni C, Petri I, Zanoni L, **Grassi I** ,Cambioli S, Fiorenzo D, Fanti S.The role of 18fdg-pet/ct for interim evaluation of therapy response in spondylodiscitis. *ejnm* vol 42 suppl1, s45-s46

16) Tabacchi E, Ghedini P, Castellucci P, **Grassi I**, Cambioli S, Fanti S. Incidentally detected increased 11c-choline uptake in bowel and hystopathological correlation *ejnm* vol 42 suppl1,s667

17) Michel Meignan, Annibale Versari, Anne Ségolène Cottreau, Loïc Chartier, Jehan Dupuis, Sami Boussetta, **Ilaria Grassi**, Rene-Olivier Casasnovas, Corinne Haioun, Hervé Tilly, Massimo Federico, Gilles A. Salles, Stefano Luminari, Judith Trotman Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies. Oral poster at 57 ASH,online published in december 3, 2015, *Blood*: 1vol 26, issue 23, page 3919.

18) Anne Segolene Cottreau, AnnibalE Versari, JehanDupuis, Loic Chartier, **Ilaria Grassi**, Stephanie Becker, Corinne Haioun, Stefano Luminari,Michel Meignan, and Judith Trotman Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor BurdenFollicular Lymphoma, *JNM* vol 57, suppl2, may 2016(abstract/poster)

19) G. Paganelli, M. Sansovini, A. Ianniello, L. Bodei, S. Nicolini, **I. Grassi**, V. Lanzetta, A. Sarnelli, I. Toni, C. Grana, M. Monti, S. Severi, 177LU DOTATATE peptide receptor radionuclide therapy in combination with metronomic capecitabine in GEP-NENS with high glucose metabolism. Preliminary data of the LUX prospective phase II study, *Clin Transl Imaging* (2017), 5 (Suppl 1): S1-S153

20) **I. Grassi**, M. Sansovini, S. Severi, S. Nicolini, A. Ianniello, F. Matteucci, L. Fantini, T. Ibrahim, A. Bongiovanni, M. MontiE. Scarpi, D. Barone, F. Ferroni, G. Paganelli 177 LU-DOTA-octreotate therapy in advanced gastrointestinal neuroendocrine tumors: outcomes after 5 years follow up. *Clin Transl Imaging* (2017), 5 (Suppl 1): S1-S153

21) S. Nicolini, S. Severi, A. Ianniello, , **I. Grassi**, M. Sansovini V. Di Iorio, E. Mezzenga, , V. Turri, M. Bocchini, F. Di Mauro, , A. Bongiovanni, G. Paganelli Toxicity and efficacy profile of PRRT with 177LU DOTATATE in GEP-NEN patients with high grade Ki67, *Clin Transl Imaging* (2017), 5 (Suppl 1): S1-S153

22) M. Sansovini, **I. Grassi**, S. Severi, A. Ianniello, S. Nicolini, M. Celli, E. Amadori, V. Di Iorio, M. Monti, E. Scarpi, A. Bongiovanni, A. Lambertini,, C. Grana, G. Paganelli; 177 Lu-Dota-octreotate therapy in advanced Gastrointestinal Neuroendocrine tumors: outcomes after 5 years follow up. *Eur J Nucl Med Mol Imaging* (2017) 44 (Suppl 2):S119–S956

23) **I.Grassi**, G. Pontone, F. Albertini, C.Orzincolo, E. Del Giudice Concordance between MRI and 99mTc-HMPAO WBCs scan in suspect osteomyelitis: results from a single centre experience. *Eur J Nucl Med Mol Imaging* (2017) 44 (Suppl 2):S119–S95

24) M. Sansovini, , G. Paganelli, S. Nicolini, **I Grassi**, V. Di Iorio, E. Amadori, E. Scarpi, A. Bongiovanni, C. Cittanti, L. Urso, S. Severi. 177 Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: ten-year follow 9-CV dr. Iliara Grassi

up of the IRST-Phase II prospective study. *European Journal of Nuclear Medicine and Molecular Imaging* (2020) 47 (Suppl 1): S1–S753 S1. DOI: 10.1007/s00259-020-04988-4

25) S. Severi, S. Zovato, S. Nicolini, **I. Grassi**, M. Sansovini, E. Tardelli, E. Scarpi, E. Mezzenga, V. Di Iorio, G. Paganelli. Patients with Progressive Paraganglioma Consecutively Treated with 177Lu-Dotatate or 90Y-Dotatoc PRRT. Toxicity, Efficacy and Prognostic Biomarker Results after Long-Term Follow-Up. *European Journal of Nuclear Medicine and Molecular Imaging* (2020) 47 (Suppl 1): S1–S753 S1. DOI: 10.1007/s00259-020-04988-4

26) G. Paganelli, S. Severi, M. Sansovini, S. Nicolini, **I. Grassi**, F. von Eyben, V. Conteduca, M. Monti, F. Foca, G. Gurioli, M. Celli, F. Matteucci, U. De Giorgi. Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results of a phase 2

Trial. *European Journal of Nuclear Medicine and Molecular Imaging* (2020) 47 (Suppl 1): S1–S753 S1. DOI: 10.1007/s00259-020-04988-4

27) M. Bocchini, M. Mazza, G. Simonetti, M. Tazzari, F. Piccinini, S. Ravaioli, F. Foca, M. Tebaldi, F. Nicolini, **I. Grassi**, S. Severi, G. Paganelli. Novel miRNA-based assay for GEP-NENs management. *Annals of Oncology* (2020) 31 (suppl_4): S505-S506. 10.1016/annonc/annonc272

28) **I. Grassi** M. Monti, S. Nicolini, M. Sansovini, F. Foca, M. Caracciolo, A. Corrado, L. Fabbri, V. Fausti, S. Severi, G. Paganelli Comparison Between Standard and Intensive Radionuclide Therapy with 177LU-DOTATATE in Advanced Neuroendocrine Tumors: Preliminary Results from a Randomized Phase II Study. *European Journal of Nuclear Medicine and Molecular Imaging* (2021) 48 (Suppl 1): S1–S648 S1. DOI: 10.1007/s00259-021-05547-1

29) A. Bongiovanni, S. Nicolini, F. Foca, T. Ibrahim, M. Sansovini, **I. Grassi**, C. Liverani, N. Riva, M. Bocchini, A. Moretti, F. Matteucci, L. Fabbri, M. Signoretti, C. A. Pacilio, R. Galassi, G. Paganelli, S. Severi. 177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: a joint analysis of phase II prospective clinical trials. *Annals of Oncology* (2021), VOLUME 32, SUPPLEMENT 5, S912, SEPTEMBER 01, 2021 <https://doi.org/10.1016/j.annonc.2021.08.185>

30) A. Bongiovanni, S. Nicolini, F. Foca, T. Ibrahim, M. Sansovini, **I. Grassi**, C. Liverani, N. Riva, M. Bocchini, A. Moretti, F. Matteucci, L. Fabbri, M. Signoretti, A. Pacilio, R. Galassi, G. Paganelli, S. Severi 177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: a joint analysis of phase II prospective clinical trials *European Journal of Nuclear Medicine and Molecular Imaging* (2021) 48 (Suppl 1): S1–S648 S1. DOI: 10.1007/s00259-021-05547-1

31) M. Bocchini, **I. Grassi**, S. Nicolini, M. Tazzari, S. Ravaioli, F. Piccinini, F. Foca, M. Tebaldi, S. Severi, M. Mazza, G. Paganelli, M. Sansovini Circulating mirnas as prognostic biomarkers in advanced gastroenteropancreatic neuroendocrine tumors. correlation with peptide receptor radionuclide therapy efficacy, 18FDG and 68GA-Dotatoc pet uptake *Clin Transl Imaging* (2022) 10 (Suppl 1):S1–S111

32) M. Caracciolo, M. Sansovini, S. Nicolini, **I. Grassi**, C. Cittanti, F. Foca, V. Di Iorio, I. Marini, M. L. Belli, L. Urso, A. Di Paolo, G. Paganelli, S. Severi 177LU-PSMA radioligand therapy in advanced prostate cancer: preliminary results of a IRST “Dino Amadori” prospective phase II clinical trial *Clin Transl Imaging* (2022) 10 (Suppl 1):S1–S111

33) L. Piscopo, S. Nicolini, M. Sansovini, L. Bodei, **I. Grassi**, F. Foca, M. Monti, C. Cuni, F. Bagnolati, I. Marini, A. Di Paolo, G. Paganelli, S. Severi. Five years follow up of “LU-X” trial: combined use of 177LUDotatate and metronomic capecitabine in FDG-positive gastroenteropancreatic neuroendocrine tumors *Clin Transl Imaging* (2022) 10 (Suppl 1):S1–S111

Chapters of books

S. Severi M. Sansovini Grassi I S. Nicolini Sarnelli A. PSMA based radioligand therapy with beta and alpha emitters in advanced prostate cancer, pp. 108-120 Nuclear medicine in prostate cancer management

S. Severi M. Sansovini Grassi I S. Nicolini Sarnelli A. targeted alpha therapy (TAT) with ²²⁵Ac PSMA pp 121-125 Nuclear medicine in prostate cancer management

OTHER INFORMATION

Foreign language: English, certification issued by the University Language Centre, Bologna.
Excellent reading ability, Excellent writing ability, Excellent oral expression ability

Organizational and relational skills and competences

- ability to work in group and expert in stress management systems in the various relational fields (qualification as pneisystem[®]EXPERT)
- Participation in multidisciplinary groups in IRST and LHA of Romagna
- During nuclear medicine residency, organization of scientific meetings for the staff weekly from October 2013 to July 2014, on behalf of the Director prof S. Fanti
- at Santa Maria Nuova Hospital, IRCCS, Reggio Emilia, participation in PDTA meetings for Lymphomas and PDTA for breast cancer.

Computer and technical skills

- excellent knowledge of the main workstations and processing programmes used in nuclear medicine
- excellent knowledge of the main Windows packages[®]

Best regards

Dott.ssa Ilaria Grassi